Arylamine N-acetyltransferases and drug response

Pharmacogenomics

Volumn 3, Issue 3, 2002, Pages 349-366

  Meisel, Peter ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

Drug response; Individualization; N acetyltransferase; Polymorphism; Side effects

Indexed keywords

ACEBUTOLOL; AMANTADINE; AMINOBENZOIC ACID; AMINOGLUTETHIMIDE; AMINOSALICYLIC ACID; AMONAFIDE; AMRINONE; AROMATIC AMINE; ARYLAMINE ACETYLTRANSFERASE; BENZOCAINE; CAFFEINE; CARCINOGEN; CLONAZEPAM; DAPSONE; DIHYDRALAZINE; DIPYRONE; DRUG METABOLITE; HYDRALAZINE; HYDRAZINE DERIVATIVE; ISONIAZID; NITRAZEPAM; NORAMIDOPYRINE; PHENELZINE; PROCAINAMIDE; SALAZOSULFAPYRIDINE; SULFADIMIDINE; SULFAPYRIDINE; SULFONAMIDE; UNINDEXED DRUG; XENOBIOTIC AGENT;

CONTROLLED STUDY; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG ELIMINATION; DRUG INDICATION; DRUG METABOLISM; DRUG RESPONSE; DRUG SENSITIVITY; DRUG USE; ENZYME ACTIVITY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENOTYPE; HEART DISEASE; HEMATOLOGIC DISEASE; HUMAN; HUMAN TISSUE; IN VIVO STUDY; LUNG TUBERCULOSIS; NEUROLOGIC DISEASE; OCCUPATION; PHENOTYPE; PREDICTION; REVIEW; RISK ASSESSMENT; SIDE EFFECT;

ANIMALS; ARYLAMINE N-ACETYLTRANSFERASE; HUMANS; PHARMACEUTICAL PREPARATIONS; POLYMORPHISM, GENETIC; XENOBIOTICS;

EID: 0036265743     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/14622416.3.3.349     Document Type: Review

References (256)

1. Pharmacogenomics: The promise of personalized medicine
2. Enzymatic inactivation of isonicotinic acid hydrazide in human and animal organisms
3. Metabolism of isoniazid in man is related to the occurrence of peripheral neuritis
4. The acetylator genes and drug response
5. Acetyltransferases
6. Genetic factors in drug therapy
7. Metabolic polymorphisms affecting activation of toxic and mutagenic arylamines
8. N-acetyltransferase polymorphisms and colorectal cancer: A HuGE review
9. Arylamine N-acetyltransferase activity in man
10. N-acetyltransferase
11. Human acetyltransferase polymorphisms
12. Pharmacogenetics of the human arylamine N-acetyltransferases
13. N-acetyltransferases, O-acetyltransferases and N,O-acetyltransferases: Enzymology and bioactivation
14. Update on consensus arylamine N-acetyltransferase gene nomenclature
15. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms
16. N-Acetyltransferase genetics and their role in predisposition to aromatic and heterocyclic amine-induced carcinogenesis
17. Drug acetylation in liver disease
18. Molecular mechanisms of genetic polymorphisms of drug metabolism
19. An update on genetic, structural and functional studies of arylamine N-acetyltransferases in eukaryotes and procaryotes
20. Arylamine N-acetyltransferases-of mice, men and microorganisms
21. Nomenclature for N-acetyltransferases
22. Scientific and ethical aspects of genetic screening of workers for cancer risk: The case of the N-acetyltransferase phenotype
23. Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-transferase and epoxide hydrolase enzymes: Relevance to xenobiotic metabolism and toxicity
24. Structure and restriction fragment length polymorphism of genes for human liver arylamine N-acetyltransferases
25. Sequences and expression of alleles of polymorphic arylamine N-acetyltransferase of human liver
26. Human arylamine N-acetyltransferase genes: Isolation, chromosomal localization and functional expression
27. Polymorphisms of N-acetyltransferase genes
28. Identification of single-nucleotide polymorphisms (SNPs) of human N-acetyltransferase genes NAT1, NAT2, AANAT, ARD1 and L1CAM in the Japanese population
29. Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans
30. Metabolic gene polymorphism frequencies in control populations
31. Structure-function studies of human arylamine N-acetyltransferases NAT1 and NAT2. Functional analysis of recombinant NAT1/NAT2 chimaeras expressed in Escherichia coli
32. Molecular genetics of human polymorphic N-acetyltransferase: Enzymatic analysis of 15 recombinant wild type, mutant and chimeric NAT2 allozymes
33. Placental arylamine N-acetyltransferase Type 1: Potential contributory source of urinary folate catabolite p- acetamidobenzoylglutamate during pregnancy
34. Purification of recombinant human N-acetyltransferase Type 1 (NAT1) expressed in E. coli and characterization of its potential role in folate metabolism
35. Human N-acetylation of benzidine: Role of NAT1 and NAT2
36. Primary aromatic amines: Their N-oxidative bioactivation
37. Initiation of autoimmunity by a reactive metabolite of a lupus-inducing drug in the thymus
38. Free radicals produced during the oxidation of hydrazines by hypochlorous acid
39. Aminobenzoic acid compounds as HOCl traps for activated neutrophils
40. Activation of 2-aminofluorene by prostaglandin endoperoxide H synthase-2
41. Arachidonic acid-dependent peroxidative activation of carcinogenic arylamines by extrahepatic human tissue microsomes
42. CYP2C8/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone
43. Development of dapsone toxicity in patients with inflammatory dermatoses: Activity of acetylation and hydroxylation of dapsone as risk factors
44. Involvement of CYP2D6 activity in the N-oxidation of procainamide in man
45. Molecular genetics of the N-acetyltransferases
46. Myeloperoxidase as a generator of drug free radicals
47. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: Correlation with phenotypic activity
48. Expression of N-acetyltransferase (NAT) in cultured human uroepithelial cells
49. Correlation between N-cetyltransferase activity and NAT2 genotype in Chinese males
50. Genotyping of N-acetylation polymorphism and correlation with procainamide metabolism
51. Polymorphic arylamine N-acetyltransferase (NAT2) genes in children with insulin-dependent diabetes mellitus
52. A simplified assay for the arylamine N-acetyltransferase 2 polymorphism validated by phenotyping with isoniazid
53. Interindividual and intraindividual variability in acetylation: Characterization with caffeine
54. Pharmacokinetics of acebutolol enantiomers in humans
55. Pharmacokinetics of beta-adrenoceptor blocking agents: Clinical significance of hepatic and/or renal clearance
56. Acebutolol: A review of its pharmacology, pharmacokinetics, clinical uses and adverse effects
57. Clinical pharmacology of acebutolol
58. Amantadine acetylation may be effected by acetyltransferases other than NAT1 or NAT2
59. A revision of the metabolic disposition of amantadine
60. Metabolism of ethyl 4-aminobenzoate in the isolated single-pass perfused rabbit ear
61. Photoallergic contact dermatitis is uncommon
62. Comparison of aminobenzoate potassium and placebo in the treatment of scleroderma
63. A comparison of morphoea and lichen sclerosus et atropicus in vitro: The effects of para-aminobenzoate on skin fibroblasts
64. Introduction to chemotherapy and antineoplastic pharmacology in breast cancer
65. Polymorphically acetylated aminoglutethimide in humans
66. Immunotherapeutic approaches to inflammatory bowel diseases
67. Kinetic phenotypic diagnosis of N-acetylation polymorphism in patients based on ratio of urinary metabolites of salicylazosulfapyridine
68. Liver and gut mucosa acetylation of mesalazine in healthy volunteers
69. 5-Aminosalicylic acid containing drugs. Delivery, fate and possible clinical implications in man
70. Identification and characterization of variant alleles of human acetyltransferase NAT1 with defective function using p-aminosalicylate as an in-vivo and in-vitro probe
71. Pharmacogenetics of anticancer agents: Lessons from amonafide and irinotecan
72. Pharmacogenetics: A tool for individualizing antineoplastic therapy
73. Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender
74. Pharmacokinetics and hemodynamics of amrinone in patients with chronic cardiac failure of diverse aetiology
75. Effect of the acetylator phenotype on amrinone pharmacokinetics
76. The role of amrinone in treating heart failure during and after coronary artery surgery supported by cardiopulmonary bypass
77. Clinical effectiveness of lidocaine and benzocaine for topical anesthesia
78. Allergic contact dermatitis from benzocaine ointment during treatment of herpes zoster
79. In vitro skin absorption and metabolism of benzoic acid, p-aminobenzoic acid and benzocaine in the hairless guinea-pig
80. Caffeine citrate: A review of its use in apnoea of prematurity
81. Risks and benefits of therapies for apnoea in premature infants
82. Pharmacological rationale for the clinical use of caffeine
83. The use of caffeine as a metabolic probe for human drug metabolizing enzymes
84. Clonazepam disposition in pediatric patients
85. Clonazepam pharmacokinetics, brain uptake and receptor interactions
86. Clonazepam acetylation in fast and slow acetylators
87. Influence of acetylator phenotype on the haematological and biochemical effects associated with dapsone in leprosy patients
88. Comparison of the metabolism and toxicity of dapsone in rat, mouse and man
89. Relationship between high incidence of adverse dapsone reactions and slow acetylate phenotype or low plasma/lymphocyte glutathione level
90. Scleroderma is associated with differences in individual routes of drug metabolism: A study with dapsone, debrisoquin and mephenytoin
91. N-substituted benzamides inhibit NFkappaB activation and induce apoptosis by separate mechanisms
92. N-substituted benzamides inhibit nuclear factor-kappaB and nuclear factor of activated T cells activity while inducing activator protein 1 activity in T lymphocytes
93. Comparison of antitumour activity of declopramide (3-chloro-procainamide) and N-acetyl-declopramide
94. Genetic factors and risk of agranulocytosis from metamizol
95. Clinical pharmacokinetics of dipyrone and its metabolites
96. Plasma kinetics of dipyrone metabolites in rapid and slow acetylators
97. The acetylation phenotype: Does it contribute to the nonlinearity of the metabolite pharmacokinetics of metamizol?
98. Acetylation and its role in the mutagenicity of the antihypertensive agent hydralazine
99. The effects of oral hydralazine on blood pressure, cardiac output and peripheral resistance with respect to dose, age and acetylator status
100. Clinical pharmacokinetics and therapeutic use of hydralazine in congestive heart failure
101. Metabolism of hydralazine in man. Part II: Investigation of features relevant to drug safety
102. The influence of the acetylator phenotype for the clinical use of dihydralazine
103. Should the acetylator phenotype be determined when prescribing hydralazine for hypertension?
104. Behavioural disorders after treatment with isoniazid
105. Isoniazid dose adjustment in a pediatric population
106. The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis
107. Trimodality of isoniazid elimination: Phenotype and genotype in patients with tuberculosis
108. Significance of the acetylator phenotype and initial oral/intravenous rifampicin administration in the treatment of tuberculosis
109. Isoniazid, rifampin and hepatotoxicity
110. Pharmacokinetics of the toxic hydrazino metabolites formed from isoniazid in humans
111. Formal genetics of isoniazid metabolism in man
112. Relationship of acetylator status to isoniazid toxicity, lupus erythematosus and bladder cancer
113. Isoniazid hepatotoxicity and acetylation during tuberculosis chemoprophylaxis
114. Clinical pharmacokinetics of isoniazid
115. Interaction of phenelzine and nitrazepam in a slow acetylator
116. Polymorphic acetylation of nitrazepam
117. Comparative developmental toxicity and metabolism of nitrazepam in rats and mice
118. High incidence of the slow nitrazepam acetylator phenotype in a Nigerian population
119. Metabolism of monoamine oxidase inhibitors
120. Chronic administration of the antidepressant-antipanic drug phenelzine and its N-acetylated analogue: Effects on monoamine oxidase, biogenic amines and alpha 2-adrenoreceptor function
121. Severe liver injury due to phenelzine with unique hepatic deposition of extracellular material
122. Metabolism and pharmacokinetics of phenelzine: Lack of evidence for acetylation pathway in humans
123. Influence of acetylator phenotype on antidepressant effects of phenelzine
124. Acetylation status in associated with serological changes but not clinically significant disease in patients receiving procainamide
125. Clinical pharmacology of antiarrhythmic drugs: Variability of metabolism and dose requirements
126. Pharmacokinetic and pharmacodynamic interaction of N-acetyl procainamide and procainamide in humans
127. Procainamide: Autoimmune phenomena and acetylator phenotype
128. Population pharmacokinetics of procainamide from routine clinical data
129. Prospective evaluation of detoxification pathways as markers of cutaneous adverse reactions to sulphonamides in AIDS
130. Association analysis of drug metabolizing enzyme gene polymorphisms in HIV-positive patients with cotrimoxazole hypersensitivity
131. The arylamine N-acetyltransferase (NAT2) polymorphism and the risk of adverse reactions to cotrimoxazole in children
132. Acetylator status and tolerance of high-dose trimethoprim-sulfamethoxazole therapy among patients infected with human immunodeficiency virus
133. A slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome
134. Multi-organ disease secondary to sulfonamide toxicity
135. Acetylation phenotype and cutaneous hypersensitivity to trimethoprim-sulphamethoxazole in HIV-infected patients
136. Pharmacokinetics and acetylation of sulfa-2-monomethoxine in humans
137. Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions
138. Influence of double genetic polymorphism on response to sulfamethazine
139. Polymorphic acetylation of sulphamethazine in man: Acetylator phenotype in sicklers and nonsicklers
140. Relationship between human genotype and phenotype of N-acetyltransferase (NAT2) as estimated by discriminant analysis and multiple linear regression 1. Genotype and N-acetylation in vivo
141. Functional characterization of nucleotide polymorphisms in the coding region of N-acetyltransferase 1
142. Functional characterization of human N-acetyltransferase 2 (NAT2) single nucleotide polymorphisms
143. Characterization of naturally-occurring and recombinant human N-acetyltransferase variants encoded by NAT1
144. The contribution of N-hydroxylation and acetylation in dapsone pharmacokinetics in normal subjects
145. Clinical pharmacokinetic considerations in the treatment of patients with leprosy
146. Lack of relevance of the axetylator status on dapsone response in chronic autoimmune thrombocytopenia purpura
147. Dihydralazine therapy and acetylator phenotype
148. Acetylator phenotype, nitrazepam plasma concentrations and residual effects
149. The relationship of acetylation phenotype to treatment with MAOIs
150. Clinical pharmacokinetic factors affecting response to phenelzine
151. Comparative bioavailability of two oral metamizole formulations. Influence of the acetylation phenotype
152. Cerebrospinal fluid isoniazid concentrations in children with tuberculous meningitis: The influence of dosage and acetylation status
153. Acecainide pharmacokinetics in normal subjects of known acetylator phenotype
154. NAT2 genotyping and efficacy of sulfasalazine in patients with chronic discoid lupus erythematosus
155. The effect of age and acetylator phenotype on the pharmacokinetics of sulfasalazine in patients with rheumatoid arthritis
156. N-acetyltransferase 2 genotype correlates with sulfasalazine pharmacokinetics after multiple dosing in healthy Japanese subjects
157. Sulphasalazine for rheumatoid arthritis: Relationship between dose, acetylator phenotype an response to treatment
158. Sulphasalazine alone or in combination with D-penicillamine in rheumatoid arthritis
159. Cloning and characterization of arylamine N-acetyltransferase genes from Mycobacterium smegmatis and Mycobacterium tuberculosis: Increased expression results in isoniazid resistance
160. Effect of acetylator phenotype on efficacy and toxicity of sulphasalazine in rheumatoid arthritis
161. Sulphasalazine: A review of 40 years' experience
162. Relationship between the acetylator phenotype, plasma sulfapyridine levels and adverse effects during treatment with salicylazosulfapyridine in patients with chronic bowel diseases
163. Practical issues in the management of hypersensitivity reactions: Sulfonamides
164. Treatment of discoid lupus erythematosus with sulfasalazine: 11 cases
165. Low N-acetylating capacity in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis
166. Cotrimoxazole induced dermatitis and curative treatment of AIDS pneumocytosis
167. Polymorphisms of the xenobiotic-metabolizing enzymes CYP1A1 and NAT-2 in systemic sclerosis and lupus erythematosus
168. Procainamide, a drug causing lupus, induces prostaglandin H synthase-2 and formation of T cell-sensitizing drug metabolites in mouse macrophages
169. N-acetyltransferase 1 and 2 polymorphisms in para-substituted arylamine-induced contact allergy
170. High capacity of human skin for N-acetylation of arylamines
171. N-Acetylation of paraphenylenediamine in human skin and keratinocytes
172. A role for bioactivation and covalent binding within epidermal keratinocytes in sulfonamide-induced cutaneous drug reactions
173. Drug-induced immune-complex disease
174. Drugs that induce systemic lupus erythematosus inhibit complement component C4
175. Hydralazine in hypertension: Is there a safe dose?
176. Immunologic effects of hydralazine in hypertensive patients
177. Predisposing factors in sulphasalazine-induced systemic lupus erythematosus
178. Genetic, immunologic and biotransformation studies of patients on procainamide
179. Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: Comparison with procainamide
180. Acecainide. A review of ist pharmacodynamic and pharmacokinetic properties and therapeutic potential in cardiac arrhythmias
181. An active agent in the treatment of previously untreated advanced breast cancer- a cancer and leukaemia group B study (CALGB 8642)
182. Paradoxical relationship between acetylator phenotype and amonafide toxicity
183. An ECOG Phase II study of amonafide in unresectable or recurrent carcinoma of the head and neck (PB390)
184. The role of acetylation in the mutagenicity of the antitumour agent, batracylin
185. N-acetylation of the heterocyclic amine batracylin by human liver
186. Dapsone-mediated agranulocytosis: Risks, possible mechanisms and prevention
187. Polymorphisms of NAT2 in relation to sulphasalazine-induced agranulocytosis
188. Sulphasalazine associated pancytopenia may be caused by acute folate deficiency
189. Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Interim report: No activity of isoniazid in the continuation phase
190. Isoniazid-induced pellagra and the N-acetyltransferase gene genotype
191. Isoniazid-induced neurotoxicity in chronic dialysis patients: Report of three cases and a review of the literature
192. Dapsone-induced peripheral neuropathy. Case report and review
193. Dapsone-induced peripheral neuropathy
194. CYP1A2 activity, gender and smoking, as variables influencing the toxicity of caffeine
195. Dapsone-induced hemolytic anemia
196. Effects of propofol on functional activities of hepatic and extrahepatic conjugation enzyme systems
197. Acetaminophen is an inhibitor of hepatic N-acetyltransferase 2 in vitro and in vivo
198. Influence of polymorphic N-acetyltransferase phenotype on the inhibition and induction of acetaminophen bioactivation with long-term isoniazid
199. All-trans-retinoic acid modulation of drug-metabolizing enzyme activities: Investigation with selective metabolic drug probes
200. Substrate-dependent regulation of human arylamine N-acetyltransferase-1 in cultured cells
201. Xanthine oxidase inhibition by allopurinol affects the reliability of urinary caffeine metabolite ratios as markers for N-acetyltransferase 2 and CYP1A2 activities
202. Inhibition of N-acetylation of procainamide and renal clearance of N-acetylprocainamide by para-aminobenzoic acid in humans
203. Effects of interferon-gamma and streptolysin O on hepatic procainamide N-acetyltransferase and various microsomal cytochrome P450-dependent monooxygenases in rats
204. Drug oxidation and N-acetylation in rats pretreated with subtoxic doses of streptolysin O
205. Effects of immunomodulator tilorone on the acetylation of 2-aminofluorene and DNA-2-aminofluorene adducts in rats
206. Immunomodulation and drug acetylation: Influence of the immunomodulator tilorone on hepatic, renal and blood N-acetyltransferase activity and on hepatic cytosolic acetyl coenzyme A content
207. Possible chloroquine-induced modification of N-acetylation of isoniazid and sulphadimidine in the rat
208. Effects of chloroquine and primaquine on rat liver cytosolic N-acetyltransferase activity
209. Effect of H2-receptor antagonists on rat liver cytosolic acetylCoA:arylamine N-acetyltransferase activity
210. Effects of ibuprofen on arylamine N-acetyltransferase activity in human colon tumour cells
211. Inhibition of N-acetyltransferase activity and DNA-2-aminofluorene adducts by glycyrrhicic acid in human colon tumour cells
212. Luteolin-inhibited arylamine N-acetyltransferase activity and DNA-2-aminofluorene adduct in human and mouse leukaemia cells
213. Paeonol promoted 2-aminofluorene and p-aminobenzoic acid acetylation by mononuclear leucocytes from Sprague-Dawley rats
214. Glucocorticoid induction of hepatic acetyl CoA:arylamine N-acetyltransferase activity in the rat
215. In vivo mechanisms for the enhanced acetylation of sulfamethazine in the rabbit after hydrocortisone treatment
216. Characterization of a hormone response element in the mouse N-acetyltransferase 2 (NAT2*) promoter
217. Tissue- and gender-specific expression of N-acetyltransferase 2 (NAT2*) during development of the outbred mouse strain CD-1
218. Epidermal N-acetylation of p-aminobenzoyl glutamic acid: Difference in response to ultraviolet B irradiation
219. Acetylation polymorphism expression in patients before and after liver transplantation: Influence of host/graft genotypes
220. The effect of liver disease on urine caffeine metabolite ratios
221. The disposition of dapsone in cirrhosis
222. Impairment of the metabolism of dipyrone in asymptomatic carriers of the hepatitis B virus
223. Dipyrone metabolism in liver disease
224. Phenylbutazone and isoniazid metabolism in patients with liver disease in relation to previous drug therapy
225. Isoniazid-associated hepatitis in 114 patients
226. Increased incidence of isoniazid hepatitis in rapid acetylators: Possible relation to hydrazine metabolites
227. Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity
228. Isoniazid and iproniazid: Activation of metabolism to toxic intermediates in man and rat
229. Hydrazine, cancer, the internet, isoniazid and the liver
230. Risk factors for hepatotoxicity during antituberculosis chemotherapy in Asian populations
231. Acetylator phenotype and genotype in patients infected with HIV: Discordance between methods for phenotype determination and genotype
232. N-acetylation among HIV-positive patients and patients with AIDS: When is fast, fast and slow, slow?
233. Altered patterns of drug metabolism in patients with acquired immunodeficiency syndrome
234. Hepatotoxicity from isoniazid and rifampin in inner-city AIDS patients
235. Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection
236. Does AIDS impair the absorption of antituberculosis agents?
237. N-acetylation genotype and risk of severe reactions to sulphonamides in AIDS patients
238. Adverse reactions to cotrimoxazole in HIV-infected patients: Predictive factors and subsequent HIV disease progression
239. Metabolic activation of aromatic and heterocyclic N-hydroxyarylamines by wild type and mutant recombinant human NAT1 and NAT2 acetytransferases
240. Current smoking, occupation, N-acetyltransferase-2 and bladder cancer: A pooled analysis of genotype-based studies
241. N-acetyl transferase-2 and bladder cancer risk: A meta-analysis
242. N-acetyltransferase 2 and bladder cancer: An overview and consideration of the evidence for gene-environment interaction
243. Colorectal cancer: Molecules and populations
244. Acetylation polymorphism and prevalence of colorectal adenomas
245. Modulation of DNA and protein adducts in smokers by genetic polymorphisms in GSTM1, GSTT1, NAT1 and NAT2
246. Immunochemical, P-postlabelling and GC/MS detection of 4-aminobiphenyl-DNA adducts in human peripheral lung in relation to metabolic activation pathways involving pulmonary N-oxidation, conjugation and peroxidation
247. Relevance of N-acetyltransferase 1 and 2 (NAT1, NAT2) genetic polymorphisms in nonsmall lung cancer susceptibility
248. A pilot study testing the association between N-acetyltransferases 1 and 2 and risk of oral squamous cell carcinoma in Japanese people
249. Association of arylamine N-acetyltransferases NAT1 and NAT2 genotypes to laryngeal cancer risk
250. Myeloperoxidase-463 (G-A) polymorphism associated with lower risk of lung cancer
251. Pharmacogenetics: The therapeutic drug monitoring of the future?
252. The clinical utility of risk factor data
253. Epidemiological evaluation of the use of genetics to improve the predictive value of disease risk factors
254. Pharmacogenetics in perspective
255. Pharmacogenetic screening and therapeutic drugs
256. Pharmacogenetics - Legal, ethical and regulatory considerations